Alexion Bets Big on Rare Diseases

by | May 11, 2015 5:44 pm | Pharmaceuticals

It was another busy week for pharmaceutical deals, but Alexion (NASDAQ: ALXN) took the prize for biggest deal with its $8.4 billion acquisition of Synageva BioPharma Corp., a privately held pharma company specializing in treatments for rare diseases. Alexion touted the fact that Synageva’s pipeline complements its own and the combined company will be one of the most robust rare disease pipelines, with more than 30 diverse pre-clinical programs. The price consists of $115 in cash and 0.6581 ALXN shares for each share of Synageva, implying a total per-share value of $230, based on the nine-day volume-weighted average closing price of Alexion stock through May 5, 2015. Read More »

Busy Year for Billion-Dollar Health Care Deals

by | May 11, 2015 5:35 pm | Other Services, Pharmaceuticals

Last week we noted that April was a slow month for healthcare deals. Then we checked our database, DealSearchOnline.com, and discovered there have been 19 billion-dollar deal announcements already in 2015, through May 8th, with a combined total of $103.6 billion. The total for the entire year is about to top $120 billion, on 487 transactions. That’s not on track to beat 2014, yet. Read More »

Optum Buys MedExpress

by | Apr 13, 2015 3:37 pm | Pharmaceuticals

UnitedHealth Group (NYSE: UNH) is still in acquisition mode. Two weeks ago its OptumRx subsidiary announced a $1.0 billion deal for pharmacy benefits manager Catamaran Corp. (NASDAQ: CTRX). Last week, another subsidiary, Optum, reached a deal for MedExpress, a privately held chain of full-service neighborhood medical centers in 11 states. Financial terms were not disclosed, but MedExpress plans to open another 25 to 30 centers in 2015. Optum plans to integrate its care management and clinical programs with MedExpress’ services. Read More »

Celgene’s Busy Week

by | Apr 4, 2015 4:38 pm | Pharmaceuticals

It wasn’t until the final week in April that Celgene Corporation (NASDAQ: CELG) took the title of top deal maker for the month. The single acquisition on the books as of April 24 was its collaboration with MedImmune (NYSE: AZN) on its anti-PD-L1 inhibitor MEDI4736, with $450 million in cash upfront. On April 27, CELG announced it would pay another $110 million for Quantical Pharmaceuticals, followed two days later by two smaller licensing deals with Northern Biologics ($30 million) and Agios Pharmaceuticals (NASDAQ: AGIO) for $10 million. Then on April 30, it reported very rosy results for the first quarter, with total revenue up 20%, to $2.08 billion, and much, much more. Read More »

Teva Acquires Auspex for its Molecules

by | Apr 4, 2015 3:27 pm | Pharmaceuticals

Teva Pharmaceuticals Industries (NYSE: TEVA) boasts that it has a portfolio of more than 1,000 molecules, which it uses to produce a wide range of generic products. Last week, the company decided it needed a few more molecules, so it agreed to pay $3.2 billion ($101 per share in cash) for Auspex Pharmaceuticals (NASDAQ: ASPX), which has 61 molecules aimed at various diseases of the central nervous system. Of course, there was a special molecule that attracted Teva: SD-809, which reported positive results from its Phase 3 clinical trial last year, as a treatment for Huntington’s disease. Read More »

Another Record Falls in Q1:15

by | Apr 4, 2015 3:19 pm | Behavioral Health Care, Biotechnology, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

Now that the month is officially over, we can report our preliminary Q1:15 results—and it was another record breaker, at least for transactions. The 346 deals logged so far are 109% higher than the first quarter of 2014. You would think that the $104.7 billion in combined spending would set another record, but no. In Q1:09, we tracked $127.2 billion spent on 202 deals. That’s when Pfizer (NYSE: PFE) bought Wyeth for $68 billion.  Here’s the preliminary breakdown of Q1:15 — and remember, the spending is only for deals that disclosed prices. Read More »